

ISOLATION OF ANTICANCER COMPOUNDS FROM EXTRACTS OF
SELECTED BASIDIOMYCETES FROM KENYA



NJUE ALICE WANJIKU



EGERTON UNIVERSITY LIBRARY

A Research Thesis Submitted to the Graduate School in Partial Fulfilment of the
Requirements for the Award of the Degree of Doctor of Philosophy in Chemistry
of Egerton University



EGERTON UNIVERSITY

OCTOBER 2017

EGERTON UNIVERSITY LIBRARY

2018 108436

ABSTRACT

Tropical basidiomycetes comprise a vast and yet largely untapped source of useful new pharmaceutical products. Compounds isolated from basidiomycetes' fruiting bodies, exhibit promising activity against tumours *in vitro* and *in vivo*. Some have been employed clinically as antitumor drugs. As different types of cancers emerge, there is need of more novel and target specific drugs. These drugs can be anticancer compounds isolated from basidiomycetes which can either be a possible alternative or increase the number of drugs controlling cancer. In this work, the basidiomycetes investigated were collected from fields of Egerton University, Mau Forest, Kerio Valley in Kenya. Herbarium specimens are retained in the Integrated Biotechnology Research Laboratory at Egerton University. A total of twenty-one compounds were isolated, of which four compounds had novel structures. They are namely ergosta-7,22-dien-3-acetate, 5 α ,8 α -epidioxy-6 α ,7 α -epoxyergosta-9(11),22-dien-3 β -ol, ergosta-7(8),22,24(28)-trien-3-one and ergosta-7,24(28)-dien-3-one. Fresh fruiting bodies of *Termitomyces microcarpus* collected from fields of Egerton University yielded five ergostanes and betulinic acid. Flesh *Suillus granulatus*, collected from the Mau Forest yielded two compounds. *Trametes versicolor*, a polypore collected from the Kerio valley yielded five ergostanes and one cycloartane, *Xylaria longipes* also collected from the Kerio Valley yielded four ergostanes and one cytochalasan. *Clavulina cinerea* collected from Kerio Valley yielded three ergostanes, a cyclopeptide and two pentacyclic triterpenes. The compounds isolated were fully characterised using NMR, IR and mass spectrometry. The ergostane-type sterols are common and widely distributed among the fungal metabolites however, this is the first report on the extractions of the sterols from the basidiomycetes. The compounds isolated were screened for activities against a panel of 60 human cancer cell lines derived from nine cancer types at single dose concentration of 0.001 mM. The compound 5 α ,8 α -epidioxyergosta-6,22-dien-3 β -ol isolated from *T. microcarpus* displayed considerable antiproliferative activity and was selected for an advanced assay against the full 60 cell panel at five concentrations at 10-fold dilution. Although the molecular mechanism by which cell death is induced remains to be confirmed, the compounds isolated from the basidiomycetes have shown to be a source of potential therapeutic agents for cancer treatment.

TABLE OF CONTENTS

DECLARATION AND RECOMMENDATION	ii
COPYRIGHT	iii
DEDICATION.....	iv
ACKNOWLEDGEMENT	v
ABSTRACT.....	vi
TABLE OF CONTENTS	vii
LIST OF TABLES	x
LIST OF FIGURES	xii
LIST OF ABBREVIATION AND ACRONYMS	xiii
CHAPTER ONE	1
INTRODUCTION.....	1
1.1 Background information of cancer	1
1.2 Global burden of cancer	2
1.3 Controlling cancer using compounds from basidiomycetes.....	4
1.4 Therapeutic cancer compounds from medicinal mushrooms.....	5
1.5 Statement of the problem	6
1.6 Objectives	7
1.6.1 General objective	7
1.6.2 Specific objectives	7
1.7 Justification.....	7
CHAPTER TWO	8
LITERATURE REVIEW.....	8
2.1 Compounds from basidiomycetes with anticancer activity.....	8
2.2 Ergostanes isolated from basidiomycetes	12
2.3 The mevalonate pathway to steroid synthesis	13
2.4 The genus <i>Termitomyces</i>	15
2.5 <i>Suillus granulatus</i> (L.) Roussel	18
2.6 <i>Xylaria longipes</i> Nitschke	21
2.6.1 Compounds isolated from <i>Xylaria longipes</i>	21
2.6.2 Biosynthetic pathway to cytochalasans.....	23
2.7 <i>Trametes versicolor</i> (L.) Lloyd.....	24

2.8	<i>Clavulina cinerea</i> (Bull) J. Schröt	26
CHAPTER THREE		27
MATERIALS AND METHODS		27
3.1	General experimental methods	27
3.2	Collection of the different mushrooms	27
3.2.1	Collection of <i>Termitomyces microcarpus</i> (Berk. & Broome) R. Heim	28
3.2.2	Collection of the <i>Suillus granulatus</i> (L.) Roussel.....	28
3.2.3	Collection of <i>Trametes versicolor</i> (L.) Lloyd	28
3.2.4	Collection of <i>Xylaria longipes</i> Nitschke	29
3.2.5	Collection of <i>Clavulina cinerea</i> (Bull) J. Schröt	29
3.3	Preparation of crude extracts	29
3.4	Chromatography of the crude extracts	29
3.4.1	Isolation of compounds from <i>T. microcarpus</i> (Berk. & Broome) R. Heim	30
3.4.2	Isolation of compounds from <i>S. granulatus</i> (L.) Roussel	31
3.4.3	Isolation of compounds from <i>T. versicolor</i> (L.) Lloyd	32
3.4.4	Isolation of compounds from <i>X. longipes</i> Nitschke.....	33
3.4.5	Isolation of compounds from <i>C. cinerea</i> (Bull) J. Schröt	34
3.5	NMR spectroscopy.....	35
3.6	Fourier Transform Infrared Spectroscopy (FTIR)	36
3.7	Mass Spectrometry (MS).....	36
3.8	Acetylation of hydroxylated compounds	36
3.9	Circular Dichroism.....	36
3.10	<i>In-vitro</i> screening of compounds isolated	37
CHAPTER FOUR.....		38
RESULTS AND DISCUSSION		38
4.1	Compounds from <i>T. microcarpus</i> (Berk. & Broome) R. Heim.....	38
4.1.1	Structural elucidation of dimethylincisterol (95).....	38
4.1.2	Structural elucidation of 5 α ,8 α -epidioxyergosta-6,9(11),22-trien-3 β -ol (96) ..	42
4.1.3	The proposed mechanism of the formation of the ergostanes.....	44
4.1.4	Structural elucidation of 5 α ,8 α -epidioxyergosta-6,22-dien-3 β -ol (97)	45
4.1.5	Structure elucidation of 5 α ,6 α -epoxyergosta-8(14),22-diene-3 β ,7 α -diol (98) ..	47
4.1.6	Structural elucidation of ergosta-7,22-diene-3 β ,5 α ,6 β -triol (99)	49
4.1.7	Structural elucidation of Betulinic acid (100)	51

4.1.8	<i>In vitro</i> anticancer activity of compound isolated from <i>T. microcarpus</i>	54
4.2	Compounds from <i>S. granulatus</i> (L.) Roussel.....	63
4.2.1	Structural elucidation of ergosta 5,7,22-trien-3 β -ol (101)	63
4.2.2	Structural elucidation of <i>p</i> - hydroxybenzoic acid (102)	66
4.3	Isolation of compounds from <i>T. versicolor</i> (L.) Lloyd	66
4.3.1	Structural elucidation of 9,19-cycloartane-3,29-diol (105).....	67
4.3.2	Structural elucidation of ergosta-7,22-dien-3-acetate (106).....	70
4.3.3	Structural elucidation of 5 α ,8 α -epidioxy-6 α ,7 α -epoxyergosta-9(11),22-dien-3 β -ol (107).....	72
4.3.4	Structural elucidation of ergosta-8(14),22-dien-3 β ,5 α ,6 β ,7 α -tetrol (108)	75
4.3.5	<i>In vitro</i> anticancer activity of compounds isolated from <i>T. versicolor</i>	77
4.4	Compounds from <i>X. longipes</i> Nitschke	81
4.4.1	Structural elucidation of ergosta-7,22,24(28)-trien-3 β -ol (111).....	82
4.4.2	Structural elucidation of ergosta-7(8),22,24(28)-trien-3-one (109).....	84
4.4.3	Structural elucidation of ergosta-7,24(28)-dien-3-one (110)	87
4.4.4	Structural elucidation of ergosta-4,6,8(14),22-tetraen-3-one (112).....	89
4.4.5	Structural elucidation of Zygosprin D (113)	92
4.4.6	<i>In vitro</i> anticancer activity of compound isolated from <i>X. longipes</i>	95
4.5	Isolation of compounds from <i>C. cinerea</i> (Bull) J. Schröt	99
4.5.1	Structural elucidation of lupeol (116)	99
4.5.2	Structural elucidation of β -amyrin (116).....	102
4.5.3	Structural elucidation of ergosta-7,22-dien-3 β -ol (117)	104
4.5.4	<i>In vitro</i> anticancer activity of compound isolated from <i>C. cinerea</i>	107
CHAPTER FIVE.....		109
5.0 CONCLUSION AND RECOMMENDATIONS		109
5.1	Conclusion	109
5.2	Recommendations	110
APPENDICES.....		123